NCT04285580 - A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

May 14, 2022

Study Completion Date

May 14, 2022

Conditions

Open-Angle GlaucomaOcular Hypertension

Interventions

DRUG

Bimatoprost SR

Consists of 1 Bimatoprost SR administration in the study eye.

DRUG

LUMIGAN

Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.

Trial Locations (6)

16066

Scott and Christie and Associates /ID# 232747, Cranberry Township

27101

James D Branch MD /ID# 232718, Winston-Salem

30076

Coastal Research Associates /ID# 232798, Roswell

36301

Trinity Research Group /ID# 232749, Dothan

92663-3637

The Eye Research Foundation /ID# 232694, Newport Beach

78731-4203

Keystone Research LTD /ID# 232665, Austin